Claims
- 1. A compound according to formula I
- 2. The compound according to claim 1 wherein G is selected from:
- 3. The compound according to claim 2 wherein
R1 is hydrogen (H) or alkyl; R2 or R2′ is hydroxyl (OH); R5 and R5′ are hydrogen or are taken together form a double bond with oxygen (O) or sulfur (S); and R6 and R6′ are taken together form a double bond with oxygen (O) or sulfur (S).
- 4. The compound according to claim 2 wherein R8 is CN.
- 5. The compound according to claim 1 selected from:
- 6. The compound according to claim 1 selected from:
- 7. The compound according to claim 1 selected from:
- 8. A compound according to formula Ih
- 9. The compound according to claim 8 wherein G is selected from:
- 10. The compound according to claim 9 wherein
R1 is hydrogen (H) or alkyl; and R2 or R2′ is hydroxyl (OH).
- 11. The compound according to claim 9 wherein R8 is CN.
- 12. A pharmaceutical composition, comprising:
(a) a compound according to claim 1; and (b) at least one pharmaceutically acceptable diluent or carrier.
- 13. The pharmaceutical composition according to claim 12, further comprising at least one additional therapeutic agent selected from other compounds of formula I, parathyroid hormone, bisphosphonates, estrogen, testosterone, progesterone, selective estrogen receptor modulators, growth hormone secretagogues, growth hormone, progesterone receptor modulators, anti-diabetic agents, anti-hypertensive agents, anti-inflammatory agents, anti-osteoporosis agents, anti-obesity agents, cardiac glycosides, cholesterol lowering agents, anti-depressants, anti-anxiety agents, anabolic agents, and thyroid mimetics.
- 14. The pharmaceutical composition according to claim 13, wherein the additional therapeutic agent is selected from the group consiting of growth hormone secretagogues and growth hormone.
- 15. A method for treating or delaying the progression or onset of muscular atrophy, lipodistrophy, long-term critical illness, sarcopenia, frailty or age-related functional decline, reduced muscle strength and function, reduced bone density or growth, the catabolic side effects of glucocorticoids, chronic fatigue syndrome, bone fracture repair, acute fatigue syndrome and muscle loss following elective surgery, cachexia, chronic catabolic state, eating disorders, side effects of chemotherapy, wasting, depression, nervousness, irritability, stress, growth retardation, reduced cognitive function, male contraception, hypogonadism, Syndrome X, diabetic complications or obesity, which comprises administering to a mammalian species in need of treatment a therapeutically effective amount of a pharmaceutical composition as defined in claim 1.
- 16. The method according to claim 15 further comprising administering, concurrently or sequentially, a therapeutically effective amount of at least one additional therapeutic agent selected from the group consisting of other compounds formula I, parathyroid hormone, bisphosphonates, estrogen, testosterone, progesterone, selective estrogen receptor modulators, growth hormone secretagogues, growth hormone, progesterone receptor modulators, anti-diabetic agents, anti-hypertensive agents, anti-inflammatory agents, anti-osteoporosis agents, anti-obesity agents, cardiac glycosides, cholesterol lowering agents, anti-depressants, anti-anxiety agents, anabolic agents and thyroid mimetics.
- 17. A process for preparing a compound of formula Id
- 18. A process for preparing a compound of formula Ie
- 19. The process of claim 18 wherein the protecting group is tert-Butyldimethylsilyl; the silylating reagent is tert-Butyldimethylsilyl (chloride); the reducing agent is lithium aluminum hydride or lithium borohydride; the leaving group is Tosyl; the base is potassium tert-butoxide.
- 20. A process for preparing a compound of formula XII,
- 21. A process for preparing a compound of formula XIV
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This application is a Continuation-in-Part Application of co-pending U.S. patent application Ser. No. 10/438,722, filed May 15, 2003, that claims the benefit of U.S. Provisional Application Nos. 60/381,616, filed May 17, 2002 and 60/406,711, filed Aug. 29, 2002, which are incorporated herein by reference in their entirety.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60381616 |
May 2002 |
US |
|
60406711 |
Aug 2002 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
10438722 |
May 2003 |
US |
Child |
10780415 |
Feb 2004 |
US |